Vectura Group plc Announces Successful Outcome Of Phase II Study On Inhaled Parkinson’s Disease Product – VR040

Vectura Group plc (LSE: VEC) (“Vectura”) today announces the successful outcome of a Phase II “proof-of concept” clinical study for its product, VR040, for the treatment of induced “off” periods in patients with Parkinson’s disease (PD).